---
document_datetime: 2023-09-21 21:09:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/thalidomide-bms-previously-thalidomide-celgene-epar-all-authorised-presentations_en.pdf
document_name: thalidomide-bms-previously-thalidomide-celgene-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6263269
conversion_datetime: 2025-12-19 10:48:08.478095
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging     | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-------------------------|-------------|
| EU/1/08/443/001  | Thalidomide BMS   | 50 mg      | Capsule, hard         | Oral use                  | blister (PCTFE/PVC/alu) | 28 capsules |